Main Article Content


World Health Organization histopathological grading of meningioma is associated with recurrence and clinical outcome. Grade II meningioma can be difficult to distinguish with grade I especially in case in which mitosis is not easily identified. MCM-2 and Cyclin D1 play crucial role in cell cycle and have been reported overexpressed in many malignant tumors. The aim of this observational analytic study was to analyze the differences and correlation between MCM-2 and Cyclin D1 in various meningioma grading. Immunohistochemystry with MCM-2 and Cyclin D1 was performed on 25 paraffin blocks of grade I, II and III meningiomas at the Laboratory of Anatomical Pathology, Dr. Soetomo Hospital. The immunoexpression are evaluated using Labelling Index, then analyzed statistically. The results showed significant difference in expression of MCM-2 within various meningioma grading (p=0.000) and significant difference in expression of Cyclin D1 within grade I and II also within grade I and III (p<0.050), but not in grade II and III (p>0.050). There was also positive correlation between MCM-2 and Cyclin D1 expression in various meningioma grading (rs=0.683, p=0.000). MCM-2 may play role in distinguishing various meningioma grading. Cyclin D1 can distinguish grade I and II also grade I and III, but not grade II and III. Overexpression MCM-2 was along with Cyclin D1 in various meningioma gradings.


Meningioma MCM-2 Cyclin D1

Article Details

How to Cite
Kurniawati, Y., & Fauziah, D. (2018). Analysis of Minichromosome Maintenance-2 (MCM-2) and Cyclin D1 Expression in Meningioma. Folia Medica Indonesiana, 54(3), 207–212.


  1. Alao JP (2007). The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Molecular Cancer; 6:24.
  2. Bhat AR, Wani MA, Kirmani AR, Ramzan AU (2014). Original article: Histological-subtypes and anatomical location correlated in meningeal brain tumors (meningiomas). J Neurosci Rural Pract 5, 244-249
  3. Cheng G, Zhang L, Lv W, Dong C, Wang Y, Zhang J (2015). Overexpression of cyclin D1 in meningioma is associated with malignancy grade and causes abnormalities in apoptosis, invasion and cell cycle progression. Med Oncol 32, 1-8
  4. Desai PB, Patel D (2015). A study of meningioma in relation to age, sex, site, symptoms, and computerized tomography scan features. International Journal of Medical Science and Public Health 5, 331-334
  5. Domingues P, Tablas MG, Otero A, Pascual D, Ruiz L, Miranda D, Sousa P, Goncalves JM, Lopes MC, Orfao A, Tabernero MD (2015). Genetic/molecular altera-tions of meningiomas and the signaling pathways targeted. Oncotarget 6, 71-88
  6. Gangadhar K, Santhosh D, Fatterpekar GM (2013). Imaging features of intracranial meningiomas with histopathological correlation: A relook into old disea-se. NJR 3, 14-32
  7. Gauchotte G, Rech F, Vigouroux C, Shu SFB (2012). Expression of minichromosome maintenance MCM6 protein in meningiomas is strongly correlated with histologic grade and clinical outcome. The American Journal of Surgical Pathology 2, 1-35
  8. Giaginis C, Vgenopoulou S, Vielh P, Theocharis S (2010). MCM proteins as diagnostic and prognostic tumor markers in the clinical setting. Histol Histopathol 25, 351-370
  9. Hewedi IH, Osman WM, ElMahdy MM (2011). Differential expression of cyclin D1 in human pitui-tary tumors: relation to MIB-1 and p27/Kip1 labeling indices. Journal of the Egyptian National Cancer Institute 23, 171-179
  10. Hua C, Zhao G, Li Y, Bie L (2014). Minichromosome maintenance (MCM) family as potential diagnostic and prognostic tumor markers for human gliomas. BMC Cancer 14, 1-8
  11. Hunt DPJ, Freeman A, Morris LS, Burnet NG, Bird K, Davies TW, Laskey RA, Coleman N (2002). Early recurrence of benign meningioma correlates with expression of mini-chromosome maintenance-2 pro-tein. British Journal of Neurosurgery 16, 10-15
  12. Milenkovic S, Marinkovic T, Jovanovic MB, Djuricic S, Berisavac II, Berisavac I (2008). Cyclin D1 immunoreactivity in meningiomas. Cell Mol Neurobiol 28, 907-913
  13. Moraes M, Mala CADM, Freitas RA, Galvao HC (2012). Cell proliferation markers in oral squamous cell carcinoma. J Mol Biomark Diag S, 1-5
  14. Park JK (2017). Epidemiology, pathology, clinical features, and diagnosis of meningioma. Available from 2~99 Accessed December 4, 2017
  15. Perry A, Louis DN, Budka H, von Deimling A, Sahm F, Rushing EJ, Mawrin C, Claus EB, Loeffler J, Sadetzki S (2016). Meningioma. In: (Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds.). WHO Classifi-cation of Tumours of the Central Nervous System. France, Lyon, p 232-237
  16. Razavi SM, Jafari M, Heidarpoor M, Khalesi S (2015). Original article: Minichromosome maintenance-2 (MCM2) expression differentiates oral squamous cell carcinoma from pre-cancerous lesions. Malaysian J Pathol 37, 253-258
  17. Shan YS, Hsu HP, Lai MD, Hung YH, Wang CY, Yen MC, Chen YL (2017). Cyclin D1 overexpression co-rrelates with poor tumor differentiation and prognosis in gastric cancer. Oncol Lett 14, 4517-4526
  18. Sudiana IK (2011). Patobiologi Molekuler Kanker. Jakarta, Salemba Medika